CHEMICALSEXPORTSCAPEXCDMOAGROCHEMICALSCHINA+1

India Specialty Chemicals: ₹18,000 Cr in New Capex, But Only Two Companies Are Actually Converting It to ROCE

25 Apr 2026·9 min read·Free Report

30-second version

1.PI Industries delivered Q3 FY26 revenue of ₹1,847 Cr (+18% YoY) with EBITDA margins holding at 23.1%, while its CSM export order book crossed ₹8,000 Cr — the highest in company history, anchored by 5 new molecules entering commercial scale in FY26.
2.FIIs have turned net buyers in the BSE Chemicals index after 14 months of selling, adding ~₹2,200 Cr in Q1 CY26; DIIs remain overweight with heaviest positioning in PI Industries and Navin Fluorine, suggesting institutional conviction is narrowing to quality names rather than the broad sector.
3.The sector median 1-year forward PE sits at 38x against a 5-year average of 44x — a 14% discount — but the discount is deserved for capex-burdened names like Aarti Industries where ROCE has collapsed from 19% in FY22 to ~11% in FY25; the re-rating case is stock-specific, not sector-wide.

01What's happening

The India-US partial tariff rollback announced in April 2026 — cutting duties on ~85 specialty chemical categories from 10-15% to 5-7% — is the most material policy shift for export-oriented chemical companies since the PLI push of FY22. PI Industries and Navin Fluorine are the direct beneficiaries given their heavy US-facing CSM and fluorochemical pipelines. Separately, China's domestic chemical overcapacity problem is worsening: BASF and Bayer have both publicly flagged willingness to qualify second-source Indian suppliers for 6-8 agrochemical active ingredients, a process that takes 18-24 months but represents committed pipeline. Atomgrid's new Bengaluru R&D centre — opened this month — signals that the innovation side of China+1 is finally arriving in India, not just the toll-manufacturing piece. On the results front, Navin Fluorine's Q3 FY26 EBITDA grew 31% YoY to ₹118 Cr as its CDMO segment hit ₹96 Cr quarterly revenue for the first time, driven by a long-term contract with a top-5 global agrochemical MNC. Deepak Nitrite, however, reported a 9% YoY revenue decline in Q3 FY26 to ₹1,987 Cr as phenol and acetone spreads remained compressed, and the Dahej Phase 3 capex of ₹1,200 Cr is not expected to contribute meaningfully before Q2 FY27. SRF's fluorochemicals business continues to face pricing pressure in refrigerant gases as Chinese exports of HFCs remain aggressive despite putative capacity cuts.

02Why this matters for your portfolio

The structural argument for Indian specialty chemicals on a 2-3 year horizon is more durable now than it was in 2021-22, but for a completely different reason. In 2021, the thesis was China+1 manufacturing shift. In 2026, it is molecule-level qualification: global agrochemical and pharma companies are embedding Indian suppliers into their regulated supply chains, which creates switching costs that are genuinely sticky. PI Industries has 47 molecules in various stages of commercialisation across its CSM pipeline — each one, once qualified with a global innovator, generates 8-12 years of annuity-like revenue. That is not replicable quickly by a new entrant. Navin Fluorine's CDMO business is now operating at ~65% utilisation on its Surat multipurpose plant, with management guiding toward ₹500 Cr CDMO revenue in FY27 versus ₹340 Cr in FY26 — a 47% jump that, if delivered, will drive meaningful operating leverage given the fixed-cost-heavy nature of GMP manufacturing. From a return-on-capital perspective, PI Industries runs at ROCE of ~22% consistently, making it one of only three Indian chemical companies that can justify a 40x+ PE without being purely a growth-story bet. The India-EU trade deal framework, if finalised by end-CY26, adds another export corridor specifically for specialty and performance chemicals where EU's chemical registration requirements currently disadvantage non-EU suppliers. For a portfolio context, this sector gives you dollar-revenue exposure, a structural tailwind that does not depend on domestic consumption, and limited direct competition from listed Chinese peers — a combination that is hard to replicate in most other Indian sectors.

03Valuation check

Current multiples vs. 5-year averages. Verdict based on trailing twelve months earnings.

Company	CMP (₹)	P/E	P/B	EV/EBITDA	5yr Avg P/E	Verdict
PI IndustriesPIIND	3,081.2	38.4x(-17%)	7.2x	27.1x	46.2x	Slight Discount
Navin Fluorine InternationalNAVINFLUOR	6,452	52.3x(-11%)	9.1x	34.8x	58.7x	Slight Discount
Aarti IndustriesAARTIIND	472.75	32.1x(-17%)	3.4x	18.9x	38.5x	Fair Value
SRF LtdSRF	2,493.6	41.7x(-3%)	5.8x	22.4x	43.1x	Fair Value

* P/E based on TTM EPS. 5yr avg is mean of FY21–FY25. Data as of April 2026.

043 stocks worth watching

Fundamentally sound names with a clear thesis. Not buy/sell recommendations.

PIINDPI Industries Ltd

₹3,081.2

CMP

Why it's interesting

PI is the only Indian agrochemical company with a fully de-risked revenue model: 70%+ of revenue comes from CSM exports where contracts are multi-year and molecule-specific, making it immune to spot pricing swings that are killing commodity chemical margins. The market is underpricing the pharma CDMO pivot — PI acquired Therachem in FY24 for ~₹1,100 Cr and the integration is on track for FY27 revenue contribution of ₹400-500 Cr from pharma CSM, a segment trading at 50-60x PE in pure-play CDMO peers. At ₹3,081 against a 52-week high of ₹4,330, the stock has corrected 29% from peak purely on market sentiment, not on any fundamental deterioration.

The number that matters

CSM export order book expanded to ₹8,100 Cr in Q3 FY26 — up from ₹6,400 Cr a year ago — representing 2.2x trailing CSM revenue, which is the highest coverage ratio in the company's listed history and virtually guarantees 18%+ revenue growth through FY28 without a single new contract win.

The risk

PI's top 3 global innovator clients account for an estimated 55-60% of CSM revenue; if any one of them internalises production or qualifies a Chinese competitor post any China-US trade détente, the order book visibility collapses faster than the 2-year commercialisation cycles suggest.

₹2,70052-week range₹4,330

CMP: ₹3,081.2 · 52-wk: ₹2,700–₹4,330 · Mkt cap: ₹46,800 Cr

Not a buy/sell recommendation. Do your own research.

NAVINFLUORNavin Fluorine International Ltd

₹6,452

CMP

Why it's interesting

Navin is the cleanest CDMO play in listed Indian chemicals — its high-performance products (HPP) and CDMO segments now contribute 58% of revenue versus 38% three years ago, and this mix shift is the entire valuation story. The Dahej CDMO plant expansion to 150 KL capacity from current 90 KL is on track for commissioning by Q2 FY27, which will unlock the revenue ramp on an already-signed contract pipeline. The stock is 7% below its 52-week high with improving fundamentals, unlike most peers where the gap from peak reflects real business deterioration.

The number that matters

CDMO segment revenue hit ₹96 Cr in Q3 FY26 — the first time it crossed ₹90 Cr in a single quarter — and management's FY27 guidance of ₹500 Cr implies the segment alone will generate more revenue next year than the entire company did from HPP+CDMO combined in FY23, with structurally higher margins of 28-32% EBITDA versus 19% for legacy refrigerants.

The risk

Navin's CDMO business is dangerously concentrated — the top 2 CDMO clients are estimated to represent 70%+ of that segment's revenue, and a clinical trial failure at either client would cause a sharp volume deceleration that the current ₹31,900 Cr market cap is not discounting.

₹4,189.452-week range₹6,965

CMP: ₹6,452 · 52-wk: ₹4,189.4–₹6,965 · Mkt cap: ₹31,900 Cr

Not a buy/sell recommendation. Do your own research.

AARTIINDAarti Industries Ltd

₹472.75

CMP

Why it's interesting

This is not a buy — it is the sector's most visible value trap. Aarti is 40% below its FY22 peak, and on the surface ₹472 looks cheap against historical PEs of 40-50x. But the ₹3,800 Cr net debt pile, the deferred long-term contract volumes, and a capex programme that has consumed cash without generating proportionate returns means the earnings recovery that consensus is modelling for FY27 requires simultaneous volume pick-up, margin normalisation, and stable benzene prices — three variables that have not aligned in any recent quarter. Include it here as the sector's cautionary position.

The number that matters

ROCE declined from 19.2% in FY22 to 10.8% in FY25 — an 840 bps destruction over three years despite ₹3,500+ Cr of capex deployment — which means the company has been destroying value on incremental capital even as management has consistently guided for a 'strong recovery next quarter'.

The risk

Net debt of ~₹3,800 Cr against FY26 estimated EBITDA of ₹900-950 Cr puts the net debt/EBITDA ratio at 4x — a level where any revenue disappointment triggers a covenant breach risk and forces equity dilution, compounding the per-share damage for existing shareholders.

₹338.0552-week range₹495

CMP: ₹472.75 · 52-wk: ₹338.05–₹495 · Mkt cap: ₹17,100 Cr

Not a buy/sell recommendation. Do your own research.

05Contrarian take

The bear case — what the bulls are missing

Here's what the bulls are missing: the China+1 narrative is being applied uniformly to a sector where the supply response is dangerously lopsided. Between FY23 and FY26, the top 10 listed Indian specialty chemical companies announced aggregate capex of over ₹18,000 Cr. Most of this — at Aarti Industries (₹4,000 Cr multi-year programme), Deepak Nitrite (₹2,800 Cr Dahej expansion), and Gujarat Fluorochemicals (₹3,500 Cr for EV fluoropolymers) — is chasing either commodity-adjacent markets or emerging technology bets that have no guaranteed demand. Aarti Industries is the most dangerous position right now: its net debt has ballooned to ~₹3,800 Cr as of December 2025, interest costs are consuming 18% of EBITDA, and the two large long-term contracts (estimated combined value ~₹12,000 Cr over 10 years) that management cited in FY22 as the demand anchor have seen one customer — a European specialty chemical major — quietly defer volumes by 12-18 months. ROCE at Aarti has compressed 800 bps over three years. The market is pricing Aarti at ~32x trailing earnings as if the capex cycle has already succeeded — it has not. Additionally, the fluorochemical space faces a specific regulatory risk: India's HFC phase-down schedule under Kigali Amendment commitments starts biting from FY28, affecting SRF's refrigerant gas revenue which still contributes ~28% of its chemicals segment. Bulls talking about SRF's EV battery fluoropolymer opportunity are pricing in a transition that is 3-4 years away while ignoring a near-term revenue hole.

06Sources

Primary sources only · No broker reports

Enjoyed this report?

Get a new one every Monday.

Subscriber plans start at ₹499/month. Includes full archive, valuation tables, and watchlists.